CymaBay Appears Stronger Threat To Ocaliva In PBC Than Ipsen/Genfit

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

CymaBay and Genfit have been positioning their failed NASH candidates, both PPAR agonists, for approval in second-line primary biliary cholangitis. Analysts call both approvable, but say CymaBay’s drug has a better overall profile.

2023 AASLD
PPAR agonists from Genfit and CymaBay are battling for a second-line indication in PBC • Source: Scrip

Cholestatic liver disease, disorders related to slowing or stalling of the biliary system, have been fallback options for companies also working in the non-alcoholic steatohepatitis space, and two companies that struck out in NASH are on the verge of submitting their PPAR agonists for US approval in primary biliary cholangitis, where they would take on another failed NASH drug, Intercept Pharmaceuticals, Inc./Alfasigma SpA’s Ocaliva, in second-line treatment.

Key Takeaways

  • CymaBay and Ipsen/Genfit both reported successful Phase III data for treatment of PBC at the 2023 AASLD meeting.

Data were presented at the American Association for the Study of Liver Disease annual meeting for both CymaBay Therapeutics,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Ordspono Will Be Regeneron’s First Independent European Launch

 
• By Jessica Merrill

Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.

Galderma Gets First Biologic To Market With Nemluvio Approval

 
• By Jessica Merrill

Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis. 

Kerendia Could Be Next Jewel In Bayer's Pharma Crown

 
• By Kevin Grogan

CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.